 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
9 News |  |
- | GC1109 / GC Biopharma
Preclinical, Journal: Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A/J Mice Model. (Pubmed Central) - May 1, 2023
The threshold 50
- |||| GC1109 / GC Biopharma
Trial completion, Enrollment change: A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (clinicaltrials.gov) - Jan 4, 2023
P2, N=240, Completed, Sponsor: Green Cross Corporation
The threshold 50 Not yet recruiting --> Completed | N=345 --> 240
- || GC1109 / GC Biopharma
Trial completion date, Trial primary completion date: A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (clinicaltrials.gov) - Jun 24, 2021
P2, N=345, Not yet recruiting, Sponsor: Green Cross Corporation
Not yet recruiting --> Completed | N=345 --> 240 Trial completion date: Nov 2016 --> Jan 2023 | Trial primary completion date: Oct 2012 --> Aug 2022
- | GC1109 / Green Cross
Preclinical, Journal: Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model. (Pubmed Central) - Mar 9, 2021
The estimated TNA titer for 50% survival rate against lethal challenge was 197 (95% confidence interval of 149 and 260). The result suggest that GC1109 is protective against exposure to B. anthracis and the TNA titer of vaccinated serum can be an indicator for protective efficacy.
- || GC1109 / Green Cross
Clinical, P2 data, Journal: Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study. (Pubmed Central) - Sep 30, 2020
The result suggest that GC1109 is protective against exposure to B. anthracis and the TNA titer of vaccinated serum can be an indicator for protective efficacy. A new rPA anthrax vaccine GC1109 was immunogenic after three doses of intramuscular administration, and was well-tolerated.
- | GC1109 / GC Biopharma
Trial suspension, Trial primary completion date: A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (clinicaltrials.gov) - Feb 29, 2016
P2, N=299, Suspended, Sponsor: Green Cross Corporation
A new rPA anthrax vaccine GC1109 was immunogenic after three doses of intramuscular administration, and was well-tolerated. Active, not recruiting --> Suspended | Trial primary completion date: Jul 2013 --> Oct 2012
- ||| GC1109 / GC Biopharma
Enrollment closed: A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (clinicaltrials.gov) - Jun 26, 2013
P2, N=299, Active, not recruiting, Sponsor: Green Cross Corporation
Active, not recruiting --> Suspended | Trial primary completion date: Jul 2013 --> Oct 2012 Recruiting --> Active, not recruiting
- GC1109 / Green Cross
New P1 trial: Efficacy and Safety of Anthrax Vaccine, GC1109 (clinicaltrials.gov) - Jun 2, 2013
P1, N=20, Completed, Sponsor: Seoul National University Hospital
- ||||| GC1109 / GC Biopharma
New P2 trial: A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (clinicaltrials.gov) - Jun 18, 2012
P2, N=299, Active, not recruiting, Sponsor: Green Cross Corporation